Black Rock Inc. Satsuma Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.7 - $1.07 $2,130 - $3,257	-3,044 Reduced 2.23%	133,256 $93,000
Q4 2022 Feb 13, 2023	SELL	$0.61 - $5.06 $9,686 - $80,352	-15,880 Reduced 10.44%	136,300 $122,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $62,598 - $118,773	14,940 Added 10.89%	152,180 $913,000
Q2 2022 Aug 12, 2022	BUY	$2.59 - $4.3 $8,052 - $13,368	3,109 Added 2.32%	137,240 $568,000
Q1 2022 May 12, 2022	SELL	$3.78 - $5.32 $64,721 - $91,089	-17,122 Reduced 11.32%	134,131 $509,000
Q4 2021 Feb 10, 2022	BUY	$4.15 - $6.24 $2,270 - $3,413	547 Added 0.36%	151,253 $681,000
Q3 2021 Nov 09, 2021	BUY	$4.54 - $7.17 $115,007 - $181,630	25,332 Added 20.21%	150,706 $702,000
Q2 2021 Aug 11, 2021	BUY	$4.8 - $7.25 $601,795 - $908,961	125,374 New	125,374 $884,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.